Minimisation of aminoglycoside toxicity in patients with cystic fibrosis

Thorax

Volumn 51, Issue 4, 1996, Pages 369-373

  Wood, Paul J ^a   Ioannides Demos, Lisa L ^a   Li, Shu C ^a   Williams, Trevor J ^a   Hickey, Bernadette ^a   Spicer, W John ^a   Hooper, Robin E ^a   McLean, Allan J ^a,b  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Aminoglycosides; Cystic fibrosis; Ototoxicity

Indexed keywords

AMINOGLYCOSIDE; TOBRAMYCIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG TOXICITY; FEMALE; HUMAN; MALE; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; TREATMENT OUTCOME;

EID: 0029996343     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.51.4.369     Document Type: Article

References (46)

1. Smith CR, Lipsky JJ, Laskin OL, Hellmann DB, Mellits ED, Longstreth J, et al. Double-blind comparison of the nephrotoxicity and auditory toxicity of gentamicin and tobramycin. N Engl J Med 1980;302:1106-9.
2. Sawyers CL, Moore RD, Lerner SA, Smith CR. A model for predicting nephrotoxicity in patients treated with aminoglycosides. J Infect Dis 1986;153:1062-8.
3. Kapusnik JE, Hackbarth CJ, Chambers HF, Carpenter T, Sande MA. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental Pseudomonas pneumonia. J Infect Dis 1988;158:7-12.
4. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, DeBroe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22-7.
5. Gilbert DN. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 1991;35:399-405.
6. Tulkens PM. Pharmacokinetic and toxicological evaluation of a once-daily regimen versus conventional schedules of netilmicin and amikacin. J Antimicrob Chemother 1991;27: 49-61.
7. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, et al. Once-daily vs. continuous aminoglycoside dosing; efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918-32.
8. Tulkens PM. Mode of nephrotoxicity of aminoglycosides, and animal and human experience with a once daily regimen. In: Ueda Y, ed. International Symposium on Netilmicin. Professional Postgraduate Services International, 1987:10-11.
9. Henley III CM, Schacht J. Pharmacokinetics of aminoglycoside antibiotics in blood, inner-ear fluids and tissues and their relationship to ototoxicity. Audiology 1988;27: 137-46.
10. Chan GLC. Alternative dosing strategy for aminoglycosides: impact on efficacy, nephrotoxicity, and ototoxicity. Drug Intell Clin Pharm 1989;23:788-93.
11. Garrison MW, Zaske DE, Rotschafer JC. Aminoglycosides: another perspective. Drug Intell Clin Pharm 1990;24:267-71.
12. Beaubien AR, Ormsby E, Bayne A, Carrier K, Crossfield G, Downes M, et al. Evidence that amikacin ototoxicity is related to total perilymph area under the concentration-time curve regardless of concentration. Antimicrob Agents Chemother 1991;35:1070-4.
13. Li SC, Bowes G, Ioannides-Demos LL, Spicer WJ, Hooper RE, Spelman DW, et al. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients. J Antimicrob Chemother 1991; 28:561-8.
14. Pechere JC, Craig WA, Meunier F. Once daily dosing of aminoglycoside: one step forward. J Antimicrob Chemother 1991;27(Suppl C):149-52.
15. Lindsay CA, Bosso JA. Optimisation of antibiotic therapy in cystic fibrosis patients. Clin Pharmacokinet 1993;24: 496-506.
16. Prins JM, Buller HR, Kuiper EJ, Tange RA, Speelman P. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993;341:335-9.
17. Ioannides-Demos LL, Li SC, Bastone EB, Spelman DW, Hooper RE, Cousins VC, et al. Absence of toxicity in patients with malignant otitis externa following long-term treatment with high dose tobramycin. J Antimicrob Chemother 1994;34:267-74.
18. Parry MF, Neu HC. Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis. J Infect Dis 1976;134(Suppl):194-7.
19. Hodson ME, Warne JO. Respiratory problems and their treatment. Br Med Bull 1992;48:931-48.
20. McCrae WM, Raeburn JA, Hanson EJ. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum. J Infect Dis 1976;134(Suppl):191-3.
21. Pederson SS, Jensen T, Osterhammel D, Osterhammel P. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis. Antimicrob Agents Chemother 1987;31:594-9.
22. Govan JRW, Nelson JW. Microbiology of lung infection in cystic fibrosis. Br Med Bull 1992;48:912-30.
23. Li SC, Ioannides-Demos LL, Spicer WJ, Spelman DW, Tong N, McLean AJ. Prospective audit of an aminoglycoside consultative service in a general teaching hospital. Med J Aust 1992;157:308-11.
24. Touw DJ, Vinks AATMM, Heijerman HGM, Bakker W. Validation of tobramycin monitoring in adolescent and adult patients with cystic fibrosis. Ther Drug Monit 1993; 15:52-9.
25. Editorial. Pulmonary infection in cystic fibrosis - still a sticky problem. Lancet 1986;ii:1372-3.
26. Esau R, Hamilton D, Davidson AGF, Wong LTK. Toxicity of high dose tobramycin therapy in cystic fibrosis patients. Can J Hosp Pharm 1987;40:203-9.
27. Prandota J. Clinical pharmacology of antibiotics and other drugs in cystic fibrosis. Drugs 1988;35:542-78.
28. Ramsey BW, Dorkin HL, Eisenberg JD, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
29. Hsu M, Aguila HA, Schmidt VL, Munzenberger PJ, Kauffman RE, Polgar G. Individualization of tobramycin dosage in patients with cystic fibrosis. Pediatr Infect Dis 1984;3:526-9.
30. Kelly HB, Menendez R, Leland F, Murphy S. Pharmacokinetics of tobramycin in cystic fibrosis. J Pediatr 1982; 100:318-21.
31. Li SC, Ioannides-Demos LL, Harrison PM, Spicer WJ, Spelman DW, Tong N, et al. Case applications of a computer-aided aminoglycoside therapeutic monitoring technique. Aust J Hosp Pharm 1989;19:147-53.
32. Freeman CD, Quintiliani R, Nightingale CH. Vancomycin therapeutic drug monitoring: is it necessary? Ann Pharmacother 1993;27:594-8.
33. Fausti SA, Henry JA, Schaffer HI, Olson DJ, Frey RH, McDonald WJ. High-frequency audiometric monitoring for early detection of aminoglycoside ototoxicity. J Infect Dis 1992;165:1026-32.
34. Rybak MJ, Boike SC, Levine DP, Erickson SR. Clinical use and toxicity of high-dose tobramycin in patients with pseudomonal endocarditis. J Antimicrob Chemother 1986; 17:115-20.
35. International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119: 584-93.
36. Gibson J, Johnson L, Snowdon L, Joshua D, Young G, MacLeod C, et al. Single daily ceftriaxone and tobramycin in the empirical management of febrile neutropenic patients: a randomised trial. Int J Hematol 1993;58:63-72.
37. TerBraak EW, DeVries PJ, Bouter KP, VanDerVegt SG, Dorrestein GC, Nortier JW, et al. Once-daily dosing regimen for aminoglycoside plus β-lactam combination therapy of serious bacterial infections: comparative trial with netilmicin plus ceftriaxone. Am J Med 1990;89:58-66.
38. Sturm AW. Netilmicin in the treatment of Gram-negative bacteremia: single daily versus multiple daily dosage. J Infect Dis 1989;159:931-7.
39. McCormack JP, Jewwesson PJ. A critical re-evaluation of the "therapeutic range" of aminoglycosides. Clin Infect Dis 1992;14:320-39.
40. Brushwood DB. Government liable for failure to monitor a patient's serum gentamicin concentration in an Army hospital. Am J Hosp Pharm 1992;49:1748-50.
41. Halmagyi GM, Costantino MF, Curthoys IS, Wade S. Gentamicin vestibulotoxicity. Otolaryngol Head Neck Surg 1994;111:571-4.
42. Tran Ba Huy P, Bernard P, Schacht J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J Clin Invest 1986; 77:1492-500.
43. Tran Ba Huy P, Deffrennes D. Aminoglycoside binding sites in the inner ears of guinea pigs. Antimicrob Agents Chemother 1988;32:467-72.
44. Pleasants RA, Williams DM, Waltner WE, Knowles MR. Influence of infusion method on serum tobramycin concentrations in adults with cystic fibrosis. Clin Pharmacol 1990;9:541-5.
45. Plumridge RJ. Cost comparison of intravenous antibiotic administrarion. Med J Aust 1990;153:516-8.
46. Parker SE, Davey PG. Once-daily aminoglycoside administration in Gram-negative sepsis. Economic and practical aspects. Pharmacoeconomics 1995;7:393-402.